secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPRUCE BIOSCIENCES, INC. (SPRB)
CIK:        0001683553
Form:       8-K
Filed at:   2024-06-03T23:59:59+00:00
Accession:  0000950170-24-067650
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Spruce Biosciences Phase 2 POWER trial shows tildacerfont reduces DHEAS (p=0.020) and increases SHBG (p=0.012) in PCOS
--------------------------------------------------------------------------------

- 27 women with PCOS enrolled; tildacerfont titrated to 200 mg QD vs placebo for 12 weeks.
- In patients with elevated baseline DHEAS, geometric mean ratio vs placebo was 0.828 (p=0.020).
- SHBG increased 32.9% vs placebo -8.1% (LS mean ratio 1.446, p=0.012).
- Tildacerfont well-tolerated; no serious adverse events reported.
- Primary endpoint not powered for significance; results suggest therapeutic potential.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1683553/000095017024067650/0000950170-24-067650-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1683553/000095017024067650/sprb-20240602.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-067650

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer